{
    "clinical_study": {
        "@rank": "136119", 
        "arm_group": {
            "arm_group_label": "Carcinoma, Irinotecan onkovis (Irinotecan)", 
            "description": "Treatment in mono- or combination therapy with Irinotecan of advanced colorectal carcinoma."
        }, 
        "brief_summary": {
            "textblock": "The main purpose of this observational study with Irinotecan onkovis is to determine the\n      number of treatment cycles and the quantity of Irinotecan onkovis needed for this purpose\n      under the special circumstances of ambulant chemotherapy.\n\n      Onkovis aims to contribute to an economical utilization of the chemotherapeutics. This\n      includes provision of appropriate packaging sizes to decrease the excess quantity to be\n      discarded, and thus also follows this objective.\n\n      Secondary objective is the assessment of the side effects of Irinotecan onkovis. To this\n      end, data regarding co-medication and adverse events are also collected."
        }, 
        "brief_title": "A Non Interventional Study With Irinotecan Onkovis (Irinotecan) Utilized for the Treatment of Cancer", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Colorectal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Indication for Irinotecan according to the SmPC and treating physician\n\n        Exclusion Criteria:\n\n          -  according to the Irinotecan SmPC"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients treated in practices, clinics, hospitals"
            }
        }, 
        "enrollment": {
            "#text": "350", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 22, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840280", 
            "org_study_id": "ONKOIRI01"
        }, 
        "intervention_browse": {
            "mesh_term": "Irinotecan"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "carcinoma", 
            "colorectal cancer", 
            "ambulant chemotherapy", 
            "treatment cycles", 
            "Irinotecan", 
            "Irinotecan onkovis", 
            "Quantity of Irinotecan", 
            "Packaging Sizes"
        ], 
        "lastchanged_date": "September 10, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Elstra", 
                        "country": "Germany", 
                        "zip": "01920"
                    }, 
                    "name": "Practice"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leipzig", 
                        "country": "Germany", 
                        "zip": "04179"
                    }, 
                    "name": "Practice"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Naunhof", 
                        "country": "Germany", 
                        "zip": "04683"
                    }, 
                    "name": "Practice"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Neustadt/Sachsen", 
                        "country": "Germany", 
                        "zip": "01844"
                    }, 
                    "name": "Practice"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Werdau", 
                        "country": "Germany", 
                        "zip": "08412"
                    }, 
                    "name": "Practice"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_groups": "1", 
        "official_title": "Open, Multicenter Observational Study of Irinotecan Utilized in Mono- or Combination Therapy for the Treatment of Advanced Colorectal Carcinoma.", 
        "overall_contact": {
            "email": "info@akp-freiburg.de", 
            "last_name": "Klaus-Ulrich Seiler, PD Dr. med.", 
            "phone": "+49(0)761479400"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Determine the quantity of Irinotecan onkovis needed pro treatment cycle", 
            "measure": "The Quantity of Irinotecan onkovis needed per treatment cycle", 
            "safety_issue": "No", 
            "time_frame": "up to 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840280"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The number and kind of adverse events during and after the intra-venous application of Irinotecan will be assessed and documented.", 
            "measure": "Adverse events during and after treatment", 
            "safety_issue": "Yes", 
            "time_frame": "up to 24 weeks"
        }, 
        "source": "Onkovis GmbH", 
        "sponsors": {
            "collaborator": {
                "agency": "AKP Freiburg GmbH (Clinical Research Organization)", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Onkovis GmbH", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "September 2013"
    }
}